Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Bayer HealthCare
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
A study to test the effectiveness of a tablet containing both Nifedipine and Candesartan Cilexetil in adults with high blood pressure whose blood pressure is not well controlled with tablets containing Nifedipine
The primary objective is to demonstrate the superior efficacy of the FDC of nifedipine GITS and candesartan cilexetil compared to nifedipine GITS monotherapy in subjects with essential hypertension no...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
A Phase III randomized, double-blind, placebo-controlled study of sorafenib as adjuvant treatment for hepatocellular carcinoma after surgical resection or local ablation
The Primary efficacy objective is to compare Recurrence Free Survival (RFS) in the patients treated with sorafenib vs placebo after receiving potentially curative treatment with surgical resection or ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
Study of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus in subjects with bone predominant HER2 negative hormone receptor positive metastatic breast cancer. Estudio de dicloruro de radio-223 en combinación con exemestano y everolimús frente a placebo en combinación con exemestano y everolimús en pacientes con cáncer de mama metastásico predominante en hueso, negativo para HER2 y positivo para los receptores hormonales
The objective of this study is to assess efficacy and safety of radium 223 dichloride in combination with exemestane and everolimus in subjects with human epidermal growth factor receptor 2 (HER2) neg...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
MAGELLaN - Multicenter, rAndomized, parallel Group Efficacy and safety study for the prevention of venous thromboembolism in hospitalized medically iLL patients comparing rivaroxabAN with enoxaparin
The objective of this study is to demonstrate (1) the superior efficacy of VTE prophylaxis with oral rivaroxaban 10 mg once daily administered for 35 +/- 4 days to SC enoxaparin 40 mg once daily (OD) ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination with Aspirin Alone or with Aspirin and a Thienopyridine in Subjects with Acute Coronary Syndromes (39039039ACS2001) The ATLAS ACS TIMI 46 Trial (Anti-Xa Therapy to Lower cardiovascular events in addition to Aspirin with or without thienopyridine therapy in Subjects with Acute Coronary Syndrome)
Stage 1 Dose Escalation The primary objective of Stage 1 (Dose Escalation) of this study is to evaluate the safety of rivaroxaban in subjects with recent acute coronary syndrome (ACS) (including ST-se...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients with Advanced Renal Cell Carcinoma
The objective of this study is to make BAY 43-9006 available for patients with advanced RCC, who failed prior systemic therapy for advanced disease (i. e., require second line treatment), and who do n...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare Pharmaceuticals
MAJ Il y a 4 ans
The purpose of this study is to describe the pharmacokinetics of moxifloxacin in children to see what the best dose should be for children in the future. Pharmacokinetics is to see how the body absorbs, distributes, breaks down and gets rid of the study drug
The primary objective of this study is to describe the pharmacokinetics of moxifloxacin in children of different ages, in order to determine a dose which will provide a similar exposure as seen in adu...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
A study, in patients with prostate cancer that has spread to the bones, investigating the efficacy of radium-223 dichloride given as a 50kBq/kg dose every four weeks or a 80kBq/kg dose every four weeks in radium-223 dichloride naive patients for six doses or as a 50kBq/kg every four weeks to patients who have already been treated with a course of six doses of radium-223 dichloride
• To evaluate efficacy as measured by symptomatic skeletal event-free survival (SSE-FS) of radium-223 dichloride 50 kBq/kg every 28 days for up to 6 doses compared to radium-223 dichloride 80 kBq/kg ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
LCS12 adolescent study
The primary objective is to assess the safety of low-dose levonorgestrel (LNG) (12μg/24h, initial in vitro release rate), delivered locally by an intrauterine contraceptive system in adolescents over ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
A study investigating the safety of radium-223 dichloride, given as a 50kBq/kg dose every four weeks to patients with castration-resistant prostate cancer that has spread to bone, who have already been treated with a course of six doses of radium-223 dichloride 50kBq/kg every four weeks. Estudio para investigar la seguridad de dicloruro de radio 223, con una dosis de 50 kBq/kg cada cuatro semanas a pacientes con cáncer de próstata resistente a la castración que se ha propagado al hueso, y que ya habían sido tratados con ciclo de seis dosis de dicloruro de radio 223 de 50 kBq/kg cada cuatro semanas
To assess the safety of re-treatment with up to 6 doses of radium-223 dichloride 50 kBq/kg given every 4 weeks in subjects with castration-resistant prostate cancer (CRPC) with bone metastases who rec...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
6
7
8
9
10
11
12
13
14
15
Suivant